Open AccessAbstract CT140: Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation study of Ipatasertib (Ipa) in combination with atezolizumab (A) in patients (pts) with advanced solid tumors (Ice-CAP)
Author(s) -
Juanita Lopez,
Andrea Biondo,
Crescens Tiu,
Mariana Scaranti,
Malaka Ameratunga,
Anna Zachariou,
Alison Turner,
Nina Tunariu,
Toby Prout,
Mona Parmar,
Hannah Badham,
Karen E. Swales,
Wei Yuan,
Ricardo Morilla,
Mateus Crespo,
Robin M. Daly,
Ines Figueiredo,
Bora Gürel,
Rita Pereira,
Ruth Riisnaes,
Igor Vivanco,
Anna Minchom,
Ben Jenkins,
Christina Yap,
Udai Banerji,
Johann De Bono
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct140
Subject(s) - medicine , rash , nausea , protein kinase b , immune system , clinical endpoint , blockade , tolerability , pi3k/akt/mtor pathway , gastroenterology , oncology , adverse effect , clinical trial , immunology , phosphorylation , signal transduction , chemistry , receptor , biochemistry